Table 2.
ABT-414 treatment emergent adverse events
| Events, n (%) | All Patients (N = 45) |
|---|---|
| All Grades (≥25% patients) | 45 (100) |
| Ocular | 40 (89) |
| Blurred vision | 29 (64) |
| Dry eye | 16 (36) |
| Keratitis | 15 (33) |
| Photophobia | 15 (33) |
| Eye pain | 12 (27) |
| Non-ocular | |
| Fatigue | 33 (73) |
| Nausea | 21 (47) |
| Thrombocytopenia | 21 (47) |
| Constipation | 20 (44) |
| Increased AST | 15 (33) |
| Increased ALT | 14 (31) |
| Seizure | 12 (27) |
| Grades 3/4 (≥10% patients) | 35 (78) |
| Ocular | 12 (27) |
| Keratitis | 6 (13) |
| Grade 3 | 6 (13) |
| Grade 4 | 0 |
| Blurred vision | 5 (11) |
| Grade 3 | 5 (11) |
| Grade 4 | 0 |
| Non-ocular | |
| Lymphopenia | 6 (13) |
| Grade 3 | 5 (11) |
| Grade 4 | 1 (2) |
| Thrombocytopenia | 6 (13) |
| Grade 3 | 2 (4) |
| Grade 4 | 4 (9) |
| Increased ALT | 5 (11) |
| Grade 3 | 5 (11) |
| Grade 4 | 0 |
| DLT (≥1 patient) | 7 (16) |
| Ocular | 4 (9) |
| Keratitis | 3 (7) |
| Blurred vision | 1 (2) |
| Eye pain | 1 (2) |
| Non-ocular | 3 (7) |
| Increased AST | 2 (4) |
| Increased ALT | 1 (2) |
| Increased gamma-glutamyltransferase | 1 (2) |
AST, aspartate aminotransferase; ALT, alanine aminotransferase; DLT, dose-limiting toxicity; GGT, gamma-glutamyltransferase.